- Home
- / C3 Biotech
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
C3 Biotech financials data including stock price, CreditSafe score, balance sheet, and acquistions and subsidiaries.
CreditSafe Score
?
Score changed on Jun 06, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| GBP | FY, 2022 | FY, 2023 | FY, 2024 |
|---|---|---|---|
| Cash | 592.7K | 276.0K | 160.1K |
| Prepaid Expenses | 2.4K | 17.1K | |
| Current Assets | 705.5K | 432.5K | 247.4K |
| PP&E | 75.0K | 103.2K | 68.7K |
| Total Assets | 1.1M | 851.6K | 721.1K |
| Accounts Payable | 1.4K | 20.6K | 51.2K |
| Current Liabilities | 276.5K | 184.4K | 255.9K |
| Total Liabilities | 427.8K | 261.8K | 279.4K |
| Common Stock | 7.0K | 7.0K | 7.0K |
| Additional Paid-in Capital | 34.3K | 34.3K | 34.3K |
| Retained Earnings | 590.5K | 548.5K | 400.4K |
| Total Equity | 631.8K | 589.8K | 441.7K |
| Financial Leverage | 1.7 | 1.4 | 1.6 |
Acquisitions & Subsidiaries
| Company name | Date | Deal size |
|---|---|---|
| Lorem | Dec 23, 2021 | $40.0M |
| Ipsum | Jan 18, 2022 | $30.0M |
| Lorem Ipsum | Feb 18, 2022 | $25.0M |
| Dolor | Oct 21, 2021 | $60.0M |
Premium Content only available in Craft’s Intelligence Portal View acquisitions and subsidiaries by company, date, and deal size. Understanding this data enables better supplier & customer negotiations and helps identify potential opportunities or market risks for your firm. Learn more |